A typical SAP-pathway MDMA-assisted therapy program in Canada costs CAD $7,500 to $15,000 out-of-pocket — the highest of the three psychedelic-assisted therapy modalities (psilocybin: ~$2,500–$6,500; ketamine: ~$1,530–$6,930). The cost is driven by the three-dosing-session protocol (vs 1–2 for psilocybin) and the more extensive preparation and integration psychotherapy frame across the ~12-week program. Drug cost is also a meaningful factor: MDMA's pharmaceutical-supply chain is more constrained than psilocybin's (no Filament-equivalent at scale providing drug at no charge to SAP patients). Insurance coverage is limited — Quebec's RAMQ public-funding precedent (Farzin/Stephan December 2022) was psilocybin-specific and has not extended to MDMA. Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD when SAP-approved — the most accessible coverage pathway for many patients given PTSD's prevalence in service-connected populations. Private insurance generally does not cover the drug; therapy fees may be partially covered as standard psychotherapy. This article walks through the cost honestly.
Key takeaways
- Typical out-of-pocket cost: CAD $7,500–$15,000 per program — highest of the three psychedelic-assisted therapy modalities.
- Cost drivers: three dosing sessions (~6–8 hrs each with two therapists), 3 preparation sessions, 9 integration sessions across the ~12-week program; more constrained drug supply chain than psilocybin.
- No Filament-equivalent free drug supply — psilocybin's Canadian-specific cost-reduction model does not apply to MDMA at scale.
- VAC considers MDMA-AT case-by-case for service-related PTSD where SAP-approved — most accessible coverage pathway.
- No Quebec RAMQ precedent for MDMA — the December 2022 Farzin/Stephan precedent was psilocybin-specific.
- Private insurance: drug not covered; therapy fees may be partially covered as standard psychotherapy.
- Alberta Blue Cross PAT (March 2024): covered ketamine; MDMA was framed as future potential once formally legalized.
Where the money goes — cost components
A typical Canadian SAP-pathway MDMA-AT program includes:
| Component | Cost (CAD) | Notes |
|---|---|---|
| Preparation sessions (3 sessions) | $450–$900 | Standard Canadian psychotherapy rates ($150–$300/session) |
| Dosing sessions (3 sessions, each ~6–8 hours with 2 therapists, clinical setting, monitoring) | $4,500–$10,500 | Largest cost component; reflects ~24 total dosing-day hours of two-therapist clinical time + facility + monitoring |
| Integration sessions (9 sessions; 3 after each dosing day) | $1,350–$2,700 | Standard psychotherapy rates |
| Drug cost (pharmaceutical-grade MDMA, 3 sessions worth) | Variable; meaningful portion of program cost | No Filament-equivalent free supply; Lykos clinical-trial supply or imported pharmaceutical MDMA |
| Intake / SAP application coordination | $0–$500 | Varies by clinic |
| Total typical program | CAD $7,500–$15,000 | Varies by provider, drug source, geographic location |
The two largest cost variables: how the clinical team is structured (one therapist + medical staff vs the standard MAPS-protocol two trained therapists) and the drug cost component (which depends on supply source).
For comparison:
- Psilocybin SAP pathway: ~CAD $2,500–$6,500 per program. Filament Health often supplies drug at no charge.
- ATMA CENA KAT pathway (ketamine): CAD $1,530–$6,930. Ketamine drug cost is a small fraction of program cost given lower per-dose pricing.
- Spravato: ~$800–$900 per session, often privately covered with prior authorization.
- MDMA-AT: substantially higher than all three, driven by protocol length and drug supply.
For the Canadian psychedelic-pricing comparison framework, see Psilocybin-Assisted Therapy Cost in Canada and Ketamine Therapy Cost in Canada.
Why MDMA-AT costs more than psilocybin or ketamine
Three structural factors:
1. Three dosing sessions vs 1–2
Most published psilocybin TRD trials use a single 25 mg dose (Goodwin 2022) or two doses (Carhart-Harris 2016, Davis 2021). Cancer-related anxiety trials use a single dose. The Bogenschutz 2022 AUD trial used two doses. MDMA's standard protocol is three dosing sessions over ~12 weeks (Mitchell 2021, Mitchell 2023). Three dosing days × ~6–8 hours each × 2 therapists adds materially to the clinical-time cost.
2. More extensive preparation and integration
The MAPS-protocol structure includes 3 preparation sessions before the first dose and 3 integration sessions after each dosing day (9 integration total). Total: ~24 sessions across the full program versus ~7–10 for psilocybin protocols. Each session at $150–$300 standard psychotherapy rates adds up.
3. Drug supply chain
Filament Health has consistently provided synthetic psilocybin to SAP-approved Canadian patients at no charge in many cases — a meaningful Canadian-specific cost reduction. No equivalent exists for MDMA at scale. Lykos Therapeutics has supplied MDMA for clinical trials; SAP-pathway supply outside trials typically incurs cost. Imported pharmaceutical MDMA through specific Health Canada authorization is also an option but with its own cost structure.
The honest framing: MDMA-AT's higher cost reflects more clinical time + more constrained drug supply rather than any structural inefficiency.
Insurance reality
Public coverage — limited
- No Canadian provincial drug plan lists MDMA. Quebec's RAMQ public-funding precedent (Farzin/Stephan December 2022) was psilocybin-specific and has not been extended to MDMA at this time.
- Other provinces: no equivalent public-funding pathway. MDMA-AT is essentially out-of-pocket for non-veteran patients.
Veterans Affairs Canada — case-by-case
VAC considers MDMA-AT case-by-case for service-related PTSD where SAP-approved. Given:
- The Mithoefer 2018 Lancet Psychiatry Phase 2 RCT specifically demonstrated efficacy in military veterans, firefighters, and police
- Service-related PTSD is the dominant Canadian SAP MDMA indication
- VAC has a documented track record of covering ketamine for service-related TRD/chronic pain (433 veterans averaged ~$10,109 in FY2024-25 ketamine coverage per VAC briefing)
VAC MDMA-AT coverage is the most accessible insurance pathway for many Canadian patients pursuing MDMA-AT. Coverage is not automatic; case-specific review applies. Typical documentation:
- Service-connected PTSD diagnosis
- Documented failure of conventional treatments (TF-CBT, PE, EMDR, SSRIs/SNRIs)
- SAP authorization in place
- Treatment plan from prescribing physician
- VAC mental-health benefits application
For the veterans pathway specifically, see MDMA-Assisted Therapy for Veterans (Wave 2 sibling article).
Other public coverage
- WSIB Ontario: covers ketamine for compensable injuries; MDMA is not on WSIB formulary at this time. Possible case-by-case review for compensable PTSD; verify with WSIB directly.
- WCB Alberta: similar — ketamine has formal pathway; MDMA does not at this time.
- Other provincial workers' compensation: case-by-case at most.
Private insurance
- Drug: essentially never covered.
- Therapy fees (preparation/integration psychotherapy): may be partially covered as standard psychotherapy when delivered by a registered profession (Registered Psychotherapist, Registered Psychologist, Registered Clinical Counsellor, Registered Social Worker depending on province).
- Alberta Blue Cross PAT (March 2024): launched covering ketamine-assisted therapy. MDMA coverage was framed as future potential once formally legalized for clinical use. Confirm current scope with Alberta Blue Cross.
Cost comparison across Canadian psychedelic-assisted therapy modalities
| MDMA-AT (SAP) | Psilocybin (SAP) | Ketamine (off-label or Spravato) | |
|---|---|---|---|
| Per-program cost | CAD $7,500–$15,000 | CAD $2,500–$6,500 | CAD $1,530–$6,930 (ATMA CENA KAT pricing) |
| Drug cost | Meaningful portion of program | Often $0 (Filament SAP supply) | Generic ketamine bundled in clinical fees; Spravato ~$800/session |
| Public coverage | None (no Quebec precedent for MDMA) | Quebec RAMQ for SAP-approved patients | Edmonton Misericordia AHCIP IV ketamine for ultra-resistant TRD |
| VAC | Case-by-case for service-related PTSD where SAP-approved | Does NOT cover psilocybin | Covers ketamine drug forms for service-related TRD/chronic pain |
| Private insurance | Drug not covered; therapy fees partial | Same | Spravato most likely privately covered; off-label generic ketamine generally not covered |
| Alberta Blue Cross PAT | Not currently covered (framed as future potential) | Not currently covered (same framing) | Covers ketamine-assisted therapy |
The honest takeaway: MDMA-AT is the most expensive psychedelic-assisted therapy in Canada and has the most limited insurance coverage — except for service-connected veterans, where VAC's case-by-case review for PTSD provides the most accessible pathway.
How ATMA CENA's clinical model affects cost
ATMA CENA's three-phase psychedelic-assisted therapy model adapts to MDMA-AT's three-dosing-session structure:
- ATMA CENA's published KAT pricing (Psychedelic Pathway $1,585+$795/additional; Psycholytic Pathway $1,530+$740/additional; Customized $2,325–$6,930) applies to ketamine. Whether these tiers apply to SAP-pathway MDMA-AT is one of the items requiring confirmation at intake given the longer dosing sessions and more extensive integration phase.
- The coordinated care model can reduce cost where the patient's existing therapist remains primary for preparation and integration, with ATMA CENA providing the dosing-day clinical infrastructure.
- Specific MDMA-AT pricing scope at ATMA CENA should be confirmed during the intake call.
Frequently asked questions
How much does MDMA-AT cost in Canada? Typically CAD $7,500–$15,000 per full program — higher than psilocybin or ketamine because of the three-dosing-session protocol and more extensive integration phase, plus more constrained drug supply.
Why is it more expensive than psilocybin therapy? Three dosing sessions vs 1–2; more preparation and integration sessions across the program; no Filament-equivalent free drug supply. The Mitchell protocol is structurally longer than psilocybin protocols.
Does VAC cover MDMA-AT for veterans? Case-by-case for service-related PTSD where SAP-approved. The most accessible insurance pathway given service-connected PTSD prevalence. See MDMA-Assisted Therapy for Veterans.
Does private insurance cover MDMA-AT? Drug essentially never covered. Therapy fees (preparation/integration psychotherapy) may be partially covered as standard psychotherapy.
Does Quebec RAMQ cover MDMA-AT? No. The December 2022 Farzin/Stephan RAMQ precedent was psilocybin-specific. Quebec MDMA-AT patients face standard out-of-pocket costs.
Does Alberta Blue Cross PAT cover MDMA-AT? The March 2024 launch covered ketamine. MDMA coverage was framed as future potential once formally legalized. Confirm current scope directly with Alberta Blue Cross.
What about WSIB / WCB workers' compensation? Ketamine has formal coverage pathways with WSIB Ontario and WCB Alberta. MDMA is not formally listed at this time. Possible case-by-case review for compensable PTSD; verify with the specific provincial workers' compensation board.
Can I get the drug at no cost like Filament psilocybin? Generally no for MDMA at this time. The Filament public-good model has no MDMA equivalent at scale. Drug cost is typically a meaningful portion of MDMA-AT program cost.
What if the cost is prohibitive? Discuss alternatives with your prescribing physician. Ketamine therapy for PTSD is the most accessible alternative with substantial published evidence (Feder 2014/2021), broader Canadian access pathways, VAC coverage, and lower per-program cost. See Ketamine Therapy for PTSD.
Does ATMA CENA offer MDMA-AT pricing tiers? ATMA CENA's published pricing tiers apply to ketamine. MDMA-AT specific pricing should be confirmed at intake given protocol differences.
Can I use my extended health plan for therapy fees? Often yes for the preparation and integration psychotherapy components when delivered by a registered profession. Direct-billing arrangements vary by clinic and plan. Confirm with the specific clinic and your insurer.
Sources
- ATMA CENA — Psychedelic-Assisted Therapy: https://psychedelic.healthcare/
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
- Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
- TheraPsil: https://therapsil.ca/
- MAPS Canada: https://www.mapscanada.org/
- Alberta Blue Cross — psychedelic-assisted therapy coverage announcement (March 2024): https://www.atmajourney.com/alberta-blue-cross-covers-pat/
- PsyCan — Sharp decline in SAP approvals: https://psychedelicscanada.org/media/
Related articles in this cluster
- MDMA-Assisted Therapy in Canada
- What Is MDMA-Assisted Therapy?
- How to Access MDMA-Assisted Therapy in Canada (SAP)
- MDMA-Assisted Therapy for PTSD
- MDMA-Assisted Therapy for Veterans
- Psilocybin-Assisted Therapy Cost in Canada
- Ketamine Therapy Cost in Canada
- Insurance Coverage for Ketamine Therapy
Last updated: 2026-05-06